OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2021.12872 OL-0-0-12872 Corrigendum Circulating extracellular vesicle-encapsulated microRNA as screening biomarkers for intraductal papillary mucinous neoplasm SatoYuki SuzukiRei TakagiTadayuki SugimotoMitsuru OhiraHiromasa 08 2021 17 06 2021 22 2 611 Copyright: © Sato et al. 2021 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

Oncol Lett 20: Article no. 315, 2020; DOI: 10.3892/ol.2020.12178

Subsequently to the publication of the above article, the authors have realized that they incorporated some wrong values for the P-values shown in Fig. 4.

A corrected version of Fig. 4 is shown opposite, featuring all the correct P-values and statistical information. Note that the errors in the Figure did not affect either the results or the conclusions reported in this study. The authors are grateful to the Editor of Oncology Letters for granting them the opportunity to publish this corrigendum, and regret any inconvenience caused to the readership of the Journal.

Expression levels of biomarkers per high-risk indicator. CA19-9 was highly expressed in patients with BO (P=0.005). Data were presented in box-and-whisker plot and error bars in figures were presented with range (minimum to maximum). CA19-9, carcinogenic antigen 19-9l EV, extracellular vesicle; miRNA/miR, microRNA; BO, biliary obstruction; MN, mural nodule; MPD, main pancreatic duct.